Overview

• WHO formalized Phase 2 data on MK-8527, confirming its safety and 30-day protective levels and endorsed six-month lenacapavir injections at the IAS 2025 conference
• The agency updated treatment guidance to include dual therapy with dolutegravir and lamivudine for patients maintaining undetectable viral loads
• Medicines Patent Pool unveiled a voluntary license covering 133 countries, including all low-income and sub-Saharan African nations, to accelerate distribution of new HIV prevention and treatment options
• WHO recommended rapid HIV self-test kits to streamline diagnosis and enable community-based delivery of long-acting prevention tools
• UNAIDS data officers warned that global budget cuts are forcing the suspension of prevention programs and could delay implementation of these breakthroughs